Donor lymphocyte infusion: The use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation

Journal of Hematotherapy and Stem Cell Research

Volumn 11, Issue 2, 2002, Pages 265-276

  Slavin, Shimon ^a   Morecki, Shoshana ^a   Weiss, Lola ^a   Or, Reuven ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD52 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FAS LIGAND; INTERLEUKIN 2 RECEPTOR; MELPHALAN; PERFORIN; THY 1 ANTIGEN;

BONE MARROW TRANSPLANTATION; DONOR; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; IMMUNOTHERAPY; LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; ANIMAL; BLOOD DISEASE; HISTOCOMPATIBILITY; IMMUNOLOGY; LYMPHOCYTE TRANSFUSION; METHODOLOGY; MORTALITY;

ANIMALS; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE TRANSFUSION; LYMPHOCYTES; STEM CELL TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036223371     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/152581602753658457     Document Type: Review

References (94)

1. Marrow transplantation for malignant diseases
2. Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation
3. Report from the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry-North America
4. Principles of cancer biology: Tumor immunology
5. Effective graft vs leukemia effects independent of graft vs host disease after T-cell depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and rIL-2
6. Rituximab: The first monoclonal antibody approved for the treatment of lymphoma
7. The role of marrow transplantation in the eradication of malignant disease
8. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation
9. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation
10. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia
11. Graft-versus-leukemia reactions after bone marrow transplantation
12. Prolongation and prevention of Rauscher virus mouse leukemia by spleen cells of naturally resistant or actively immunized mice
13. Time pattern of the antileukemia effect of graft-versus-host reaction in mice, I. Cellular events
14. Graft-versus-leukaemia reactivity induced by alloimmunization without augmentation of graft-versus-host reactivity
15. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI)
16. Characterization of alloimmunization-induced T lymphocytes reactivated against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo
17. Possibility of graft-vs-leukemia determinants independent of the major histocompatibility complex in allogeneic marrow transplantation
18. Characterization of effector cells of graft vs leukemia (GVL) following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia (BCL1)
19. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-vs-leukemia reactivity, and tolerance after bone marrow transplantation
20. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB X NZW)F1 hybrids with spontaneous lymphosarcoma
21. Induction of graft vs tumor effect in a murine model of mammary adenocarcinoma
22. Allogeneic cell therapy for a murine mammary carcinoma
23. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
24. Allogeneic peripheral-blood progenitor-cell transplantation for poorrisk patients with metastatic breast cancer
25. Allogeneic cell mediated immunotherapy for breast cancer after autologous stem cell transplantation: A clinical pilot study
26. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect
27. Increased risk of leukemia relapse with high dose cyclosporine A after allogeneic marrow transplantation for acute leukemia
28. Effect of cyclosporine A and methylprednisolone on the GVL effect across major histocompatibility barriers in mice following allogeneic bone marrow transplantation
29. Allogeneic cell therapy of severe beta thalassemia major by displacement of host stem cells in mixed chimera by donor blood lymphocytes
30. Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic BMT for beta thalassemia major
31. Mini-transplants and cell-based therapies for malignant and non-malignant disorders
32. Prevention of GVHD and induction of graft vs leukemia (GVL) effects: Will it ever be possible?
33. Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man
34. Cell-mediated cytokine-activated immunotherapy (CCI) of malignant hematological disorders for eradication of minimal residual disease (MRD) in conjunction with conventional chemotherapy or bone marrow transplantation (BMT)
35. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes
36. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation
37. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
38. Graft-versus-leukemia effect on donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia
39. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
40. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease
41. A gene mapping to the sex-determining region of the mouse y chromosome is a member of a novel family of embryologically expressed genes
42. Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT
43. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro
44. Treatment of relapse in recipients of lymphocyte depleted grafts with infusion of lymphocytes of the original bone marrow donor
45. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation
46. Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: Recovery complicated by initial pancytopenia and late dermatomyositis
47. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lympho-proliferative disorders after allogeneic bone marrow transplantation
48. Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus specific cytotoxic T lymphocytes from an HLA matched sibling to a patient with severe chronic active EBV infection
49. A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation
50. Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man?
51. Transplantation of allogeneic bone marrow without graft vs host disease using total lymphoid irradiation
52. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders.I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL2-activated cell-mediated immunotherapy
53. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease
54. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse
55. Allogeneic cell mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic BMT for hematological malignancies
56. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematological relapse
57. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms
58. The immunotherapy and gene therapy of cancer
59. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic-T cell activities
60. Generation of donor derived antileukemic cytotoxic T lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA identical bone marrow transplantation
61. Adoptive immunotherapy in conjunction with bone marrow transplantation-amplification of natural host defence mechanisms against cancer by recombinant IL2
62. Immunotherapy with recombinant human interleukin-2 (rIL-2) and recombinant α-interferon in lymphoma patients post autologous marrow or stem cell transplantation
63. Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-2a
64. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders
65. Characterization of effector cells of graft vs leukemia (GVL) following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia (BCL1)
66. Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes
67. The role of nonactivated and rIL-2 activated CD4+ and CD8+ T cells in immunotherapy for leukemia
68. Effect of deoxyspergualin on graft vs host disease and graft vs leukemia in mice
69. The role of antibodies to IL-2 receptor and anti-Asialo GMI antibodies on GVL effects induced by BMT in murine B cell leukemia
70. + T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation
71. Graft-vs-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation
72. Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukemia effect in mice
73. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
74. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation
75. Hybrid resistance to parental DBA-2 grafts: Independence from the H-2 locus.I. Studies with normal hematopoietic cells
76. CD8-depleted donor lymphocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation
77. Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immunotherapy
78. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens
79. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation
80. Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells
81. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1)
82. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
83. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases
84. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
85. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for a malignant lymphoma
86. Fludarabine based protocol for BMT in Fanconi's anemia
87. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
88. Outpatient PBSC allografts using immunosuppression with low-dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant
89. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia
90. "Mini-allografts": Ongoing trials in humans
91. Immunotherapy of cancer with alloreactive lymphocytes
92. Cell therapy with pre-immunized effector cells mismatched for minor histocompatible antigens, in the treatment of a murine mammary carcinoma
93. Cancer immunotherapy with alloreactive lymphocytes